The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant taxane plus trastuzumab and pertuzumab (THP) yields an overall 43.8% pathologic complete response rate in EA1181/CompassHER2 patients, reaching 63.7% in HER2+/ER− and 32.4% in HER2+/ER+ tumors.
- Why it matters: Clinicians need better predictors of who achieves pCR after THP in clinical stage II/IIIa HER2-positive breast cancer to refine risk stratification and personalize treatment.
- What they did: In a single-arm neoadjuvant trial, patients received four cycles of trastuzumab and pertuzumab with either once-per-week paclitaxel or every-3-weeks docetaxel, then surgery; logistic regression tested clinicopathologic factors, and HER2DX pCR scores were measured in 569 patients.
- The result: Higher pCR was linked to ER-negative or low ER, progesterone receptor-negative or low, HER2 IHC 3+, and once-per-week paclitaxel; T3 disease lowered pCR in HER2+/ER−, and a high HER2DX pCR score independently predicted higher pCR after adjustment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.